Research and Markets - Nociceptive Pain - Safety Profile Uppermost in Crowded Market.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c10173) has announced the addition of Pipeline Insight: Nociceptive no·ci·cep·tive adj. 1. Causing pain. Used of a stimulus. 2. Caused by or responding to a painful stimulus. Pain - Safety Profile Uppermost in Crowded Market to their offering. The nociceptive pain pipeline contains few novel drugs, instead being filled with reformulations and drug combinations. To make a drug stand out in this replete market, particularly at a time when there is great public concern about drug withdrawals, it must have an unquestionable safety profile, proven over long-term trials. Scope - Epidemiology of nociceptive pain across the seven major markets, as well as analysis of the main unmet needs in the current treatment of the disease - Overview of drugs in Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA , II, I and preclinical development, plus analysis of key companies involved in the R&D pipeline: GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) , Merck and Endo - Comprehensive analysis of key late-stage products including DepoDur, Ionsys, Prexige, Prialt & THC THC tetrahydrocannabinol. THC n. Tetrahydrocannabinol; a compound that is obtained from cannabis or is made synthetically; it is the primary intoxicant in marijuana and hashish. monotherapy, with drug revenues forecast to 2014 - Insight into innovative early stage products, including vanilloid and Bradykinin receptors, plus analysis of key research into gene therapy for pain Highlights - Although pain is not a new phenomenon, better education for patients, physicians, nurses and pharmacists is still an unmet need. The current range of therapies should be sufficient for pain relief if used knowledgably. - New COX-2 inhibiting drugs will have to provide impeccable safety data from long-term trials before gaining approval in the current climate where the whole class of drugs is suspect. If safety can be proved, the market is relatively small, and new entrants may do well. - While experts believe morphine is still the most effective painkiller available, it can be improved upon in terms of convenience and side effects Side effects Effects of a proposed project on other parts of the firm. . Many opioids Opioids One of the major classes of semi or fully synthetic psycho-active drugs that includes methadone. Mentioned in: Cancer Therapy, Palliative, Methadone opioid in development are reformulations of old drugs sustained release Sustained-release (SR), extended-release (ER, XR, or XL), time-release or timed-release, controlled-release (CR), or continuous-release (CR or Contin , or patch delivery or receptor-specific drugs aiming to reduce side effects. Reasons to Purchase - Enhance your sales forecasting ability and future product positioning through identification of market drivers and key competitors - Optimise your knowledge of company strategies in the nociceptive pain market - Identify areas of the market that are not being targeted by competitors TABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 3 CHAPTER 2 PATIENT POTENTIAL 31 CHAPTER 3 R&D APPROACH 56 CHAPTER 4 NOCICEPTIVE PAIN PIPELINE ANALYSIS 75 CHAPTER 5 OPIOID opioid /opi·oid/ (o´pe-oid) 1. any synthetic narcotic that has opiate-like activities but is not derived from opium. 2. any of a group of naturally occurring peptides, e.g. DRUGS LATE-STAGE DRUG ANALYSIS & FORECASTS 110 CHAPTER 6 NSAIDS LATE-STAGE DRUG ANALYSIS AND FORECASTS 163 CHAPTER 7 OTHER ANALGESICS Analgesics Definition Analgesics are medicines that relieve pain. Purpose Analgesics are those drugs that mainly provide pain relief. LATE-STAGE DRUG ANALYSIS AND FORECASTS 192 CHAPTER 8 INNOVATIVE EARLY-STAGE PROJECTS 230 APPENDIX A APPENDIX B For more information visit http://www.researchandmarkets.com/reports/c10173 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion